{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:24:30Z","timestamp":1781655870482,"version":"3.54.5"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T00:00:00Z","timestamp":1635379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To simulate and analyze the dosimetric differences of intraoperative radiotherapy (IORT) or pre-operative single-fraction stereotactic radiosurgery (SRS) in addition to post-operative external beam radiotherapy (EBRT) in Glioblastoma (GB).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Imaging series of previously treated patients with adjuvant radiochemotherapy were analyzed. For SRS target definition, pre-operative MRIs were co-registered to planning CT scans and a pre-operative T1-weighted gross target volume (GTV) plus a 2-mm planning target volume (PTV) were created. For IORT, a modified (m)GTV was expanded from the pre-operative volume, in order to mimic a round cavity as during IORT. Dose prescription was 20 Gy, homogeneously planned for SRS and calculated at the surface for IORT, to cover 99% and 90% of the volumes, respectively. For tumors &amp;gt; 2cm in maximum diameter, a 15 Gy dose was prescribed. Plan assessment was performed after calculating the 2-Gy equivalent doses (EQD2) for both boost modalities and including them into the EBRT plan. Main points of interest encompass differences in target coverage, brain volume receiving 12 Gy or more (V<jats:sub>12<\/jats:sub>), and doses to various organs-at-risk (OARs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Seventeen pre-delivered treatment plans were included in the study. The mean GTV was 21.72 cm<jats:sup>3<\/jats:sup> (SD \u00b1 19.36) and mGTV 29.64 cm<jats:sup>3<\/jats:sup> (SD \u00b1 25.64). The mean EBRT and SRS PTV were 254.09 (SD \u00b1 80.0) and 36.20 cm<jats:sup>3<\/jats:sup> (SD \u00b1 31.48), respectively. Eight SRS plans were calculated to 15 Gy according to larger tumor sizes, while all IORT plans to 20 Gy. The mean EBRT D<jats:sub>95<\/jats:sub> was 97.13% (SD \u00b1 3.48) the SRS D<jats:sub>99<\/jats:sub> 99.91% (SD \u00b1 0.35) and IORT D<jats:sub>90<\/jats:sub> 83.59% (SD \u00b1 3.55). Accounting for only-boost approaches, the brain V<jats:sub>12<\/jats:sub> was 49.68 cm<jats:sup>3<\/jats:sup> (SD \u00b1 26.70) and 16.94 cm<jats:sup>3<\/jats:sup> (SD \u00b1 13.33) (p&amp;lt;0.001) for SRS and IORT, respectively. After adding EBRT results respectively to SRS and IORT doses, significant lower doses were found in the latter for mean D<jats:sub>max<\/jats:sub> of chiasma (p=0.01), left optic nerve (p=0.023), right (p=0.008) and left retina (p&amp;lt;0.001). No significant differences were obtained for brainstem and cochleae.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Dose escalation for Glioblastoma using IORT results in lower OAR exposure as conventional SRS.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.759873","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T07:22:08Z","timestamp":1635405728000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for Glioblastoma"],"prefix":"10.3389","volume":"11","author":[{"given":"Gustavo R.","family":"Sarria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzanna","family":"Smalec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Muedder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin A.","family":"Holz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Scafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motaz","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Vatter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Herrlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank A.","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard Christopher","family":"Schmeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70025-7","article-title":"Effects of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy Alone on Survival in Glioblastoma in a Randomised Phase III Study: 5-Year Analysis of the EORTC-NCIC Trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11060-012-0983-4","article-title":"Failure Pattern Following Complete Resection Plus Radiotherapy and Temozolomide is at the Resection Margin in Patients With Glioblastoma","volume":"111","author":"Petrecca","year":"2013","journal-title":"J Neurooncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(92)91021-e","article-title":"Supratentorial Malignant Glioma: Patterns of Recurrence and Implications for External Beam Local Treatment","volume":"24","author":"Gaspar","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","article-title":"A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma","volume":"370","author":"Gilbert","year":"2014","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70379-1","article-title":"Cilengitide Combined With Standard Treatment for Patients With Newly Diagnosed Glioblastoma With Methylated MGMT Promoter (CENTRIC EORTC 26071-22072 Study): A Multicentre, Randomised, Open-Label, Phase 3 Trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.ijrobp.2008.05.034","article-title":"Phase I Three-Dimensional Conformal Radiation Dose Escalation Study in Newly Diagnosed Glioblastoma: Radiation Therapy Oncology Group Trial 98-03","volume":"73","author":"Tsien","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.07.014","article-title":"Radiation Therapy Dose Escalation for Glioblastoma Multiforme in the Era of Temozolomide","volume":"90","author":"Badiyan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.02.042","article-title":"A Phase II Trial of Accelerated Radiotherapy Using Weekly Stereotactic Conformal Boost for Supratentorial Glioblastoma Multiforme: RTOG 0023","volume":"65","author":"Cardinale","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.04.011","article-title":"Randomized Comparison of Stereotactic Radiosurgery Followed by Conventional Radiotherapy With Carmustine to Conventional Radiotherapy With Carmustine for Patients With Glioblastoma Multiforme: Report of Radiation Therapy Oncology Group 93-05 Protocol","volume":"60","author":"Souhami","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90676-u","article-title":"External Irradiation Followed by an Interstitial High Activity Iodine-125 Implant \u201cBoost\u201d in the Initial Treatment of Malignant Gliomas: NCOG Study 6G-82-2 Gliomas: NCOG Study 6H-82-2","volume":"21","author":"Gutin","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.brachy.2007.11.001","article-title":"Systemic Iodine 125 Activity After GliaSite Brachytherapy: Safety Considerations","volume":"7","author":"Adkison","year":"2008","journal-title":"Brachytherapy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10143-016-0727-6","article-title":"The Role of Brachytherapy in the Treatment of Glioblastoma Multiforme","volume":"40","author":"Barbarite","year":"2017","journal-title":"Neurosurg Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.09.023","article-title":"Intraoperative Radiotherapy for Glioblastoma: An International Pooled Analysis","volume":"142","author":"Sarria","year":"2020","journal-title":"Radiother Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyy018","article-title":"Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I\/II Trial","volume":"84","author":"Giordano","year":"2019","journal-title":"Neurosurgery"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00074","article-title":"Intraoperative Radiotherapy With INTRABEAM: Technical and Dosimetric Considerations","volume":"8","author":"Sethi","year":"2018","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijrobp.2020.08.013","article-title":"Single- and Multifraction Stereotactic Radiosurgery Dose\/Volume Tolerances of the Brain","volume":"110","author":"Milano","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-020-03667-6","article-title":"Intraoperative MRI for Brain Tumors","volume":"151","author":"Rogers","year":"2021","journal-title":"J Neurooncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clon.2005.08.017","article-title":"Mathematical Modelling of Survival of Glioblastoma Patients Suggests a Role for Radiotherapy Dose Escalation and Predicts Poorer Outcome After Delay to Start Treatment","volume":"18","author":"Burnet","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2174\/1874120700802010043","article-title":"Critical Parameters Determining Standard Radiotherapy Treatment Outcome for Glioblastoma Multiforme: A Computer Simulation","volume":"2","author":"Dionysiou","year":"2008","journal-title":"Open BioMed Eng J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-011-0015-x","article-title":"[The ICRU Report 83: Prescribing, Recording and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT)]","volume":"188","author":"Hodapp","year":"2012","journal-title":"Strahlenther Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.radonc.2013.11.002","article-title":"Review of Clinical Brachytherapy Uncertainties: Analysis Guidelines of GEC-ESTRO and the AAPM","volume":"110","author":"Kirisits","year":"2014","journal-title":"Radiother Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-018-1416-x","article-title":"ICRU Report 91 on Prescribing, Recording, and Reporting of Stereotactic Treatments With Small Photon Beams : Statement From the DEGRO\/DGMP Working Group Stereotactic Radiotherapy and Radiosurgery","volume":"195","author":"Wilke","year":"2019","journal-title":"Strahlenther Onkol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-6-48","article-title":"Stereotactic Radiosurgery for Brain Metastases: Analysis of Outcome and Risk of Brain Radionecrosis","volume":"6","author":"Minniti","year":"2011","journal-title":"Radiat Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2012.08.005","article-title":"Relative Biologic Effectiveness (RBE) of 50 kV X-Rays Measured in a Phantom for Intraoperative Tumor-Bed Irradiation","volume":"85","author":"Liu","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijrobp.2020.10.039","article-title":"High Dose Per Fraction, Hypofractionated Treatment Effects in the Clinic (HyTEC): An Overview","volume":"110","author":"Grimm","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.759873\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T07:22:10Z","timestamp":1635405730000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.759873\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,28]]},"references-count":26,"alternative-id":["10.3389\/fonc.2021.759873"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.759873","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,28]]},"article-number":"759873"}}